SARS-CoV-2 spike protein receptor binding domain promotes IL-6 and IL-8 release via ATP/P2Y2 and ERK1/2 signaling pathways in human bronchial epithelia.

The spike protein of SARS-CoV-2 as well as its receptor binding domain (RBD) has been demonstrated to be capable of activating the release of pro-inflammatory mediators in endothelial cells and immune cells such as monocytes. However, the effects of spike protein or its RBD on airway epithelial cells and mechanisms underlying these effects have not been adequately characterized. Here, we show that the RBD of spike protein alone can induce bronchial epithelial inflammation in a manner of ATP/P2Y2 dependence. Incubation of human bronchial epithelia with RBD induced IL-6 and IL-8 release, which could be inhibited by antibody. The incubation of RBD also up-regulated the expression of inflammatory indicators such as ho-1 and mkp-1. Furthermore, ATP secretion was observed after RBD treatment, P2Y2 receptor knock down by siRNA significantly suppressed the IL-6 and IL-8 release evoked by RBD. Additionally, S-RBD elevated the phosphorylation level of ERK1/2, and the effect that PD98059 can inhibit the pro-inflammatory cytokine release suggested the participation of ERK1/2. These novel findings provide new evidence of SARS-CoV-2 on airway inflammation and introduce purinergic signaling as promising treatment target.

Detection of Rickettsia spp. and Anaplasma ovis in Melophagus ovinus from southern Xinjiang, China.

Melophagus ovinus is a hematophagous insect that is distributed worldwide and plays a crucial role in transmitting disease-causing pathogens. From June 2021 to March 2022, a total of 370 M. ovinus were collected from 11 sampling points in southern Xinjiang, China. The specimens were identified using morphological and molecular analyses. Rickettsia spp. and Anaplasma ovis were detected from all the samples using seven Rickettsia-specific genetic markers and the msp-4 gene of A. ovis. Approximately 11% of the M. ovinus specimens were positive for Rickettsia spp., and Candidatus Rickettsia barbariae was the most predominant species (35/41; 85.4%), while R. massiliae was least prevalent (6/41; 14.6%). Approximately 10.5% (39/370) of the M. ovinus specimens were positive for A. ovis of genotype III, which was co-detected with Candidatus R. barbariae in M. ovinus (3/370; 0.8%). To the best of our knowledge, this is the first report of the detection of R. massiliae and Candidatus R. barbariae in M. ovinus globally. The detection and control of insect-borne diseases originating from M. ovinus should be strengthened in southern Xinjiang, an area important to animal husbandry and production.

Energy Harvesting Under Dim-Light Condition With Dye-Sensitized and Perovskite Solar Cells.

We demonstrate highly efficient energy harvesting devices for dim-light application under 200 lux irradiation using dye-sensitized solar cells (DSCs) and perovskite solar cells (PSCs). The high-efficiency DSCs are composed of cobalt-based redox mediators in 3-methoxypropionitrile (MPN) solvent with MK-2 sensitizer. With the introduction of under layer treatment and fine-tuning of compositions in cobalt-based electrolyte, the power conversion efficiency of cobalt-based DSCs achieves 16.0% under 200 lux illumination. That outperforms the best device using the conventional iodine-based electrolyte illuminated with the same light intensity. Especially, cobalt-based electrolyte system exhibits a higher open circuit voltage than iodine-based electrolyte counterpart. We also investigate perovskite solar cells under dim-light condition. PSCs show higher open circuit voltage and short circuit current density than DSCs with efficiency up to 23.4%. In this work, our results demonstrate the promising potential of DSCs and PSCs in the dim-light applications.

Analyzing the differentially expressed genes and pathway cross-talk in aggressive breast cancer.

AIM: The aim of this study was to explore the genes and pathways involved in the aggressive breast cancer cells. METHODS: The gene expression profiles of GSE40057, including four aggressive breast cell lines and six less aggressive cell lines, were downloaded from the Gene Expression Omnibus (GEO) database. The gene differential expression analysis was carried out with limma software with the method of Bayes for multiple tests. The gene ontology (GO) term enrichment and pathway cross-talk analysis were performed with the online tool of DAVID and Cytoscape software. RESULTS: A total of 401 differentially expressed genes (DEG), such as pentraxin 3 (PTX3), snail family zinc finger 2 (SNAI2), interleukin-8/6 (IL-8/6), osteonectin (SPARC), matrix metallopeptidase-1 (MMP-1) and Ras-related protein Rab-25 (Rab 25), were identified between aggressive and less aggressive cell lines. They were mainly enriched in the GO terms of response to wounding, negative regulation of cell proliferation and calcium binding. Pathways in cancer dysfunctionally interacted with glyoxylate and dicarboxylate metabolism (P < 0.0001), basal transcription factors (P < 0.0001), tyrosine metabolism (P < 0.0001), calcium signaling pathway (P = 0.0021), FcγR-mediated phagocytosis (P = 0.0022), metabolism of xenobiotics by cytochrome P450 (P = 0.0097) and phagosome (P = 0.0102). CONCLUSION: The screened aggressive cancer-associated DEG (PTX3, SNAI2, IL-8/6, SPARC, MMP-1 and Rab25) and significant pathways (calcium signaling pathway, tyrosine metabolism, alanine, aspartate and glutamate metabolism) give us new insights into the mechanism of aggressive breast cancer cells, and these DEG may become promising target genes in the treatment of metastatic breast cancer.

[Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].

BACKGROUND & OBJECTIVE: Gemcitabine combined with cisplatin has been taken as the front-line regimen for patients with advanced non-small-cell lung cancer (NSCLC). The routine use of gemcitabine is intravenous injection of a dose of 1,000 mg/m(2) within 30 minutes on days 1 and 8, and the treatment is repeated every 3 weeks. This study was to evaluate the efficacy and safety of 6-hour continuous infusion of low dose of gemcitabine plus cisplatin for patients with advanced NSCLC. METHODS: Forty-eight patients with measurable stage III B/IV NSCLC and without chemotherapy were enrolled. All of them received 6-hour continuous infusion of gemcitabine 250 mg/m(2) on day 1 and 8 plus cisplatin 75 mg/m(2) on day 2-4 for more than 2 cycles. The cycle was repeated every 3 weeks. RESULTS: All 48 patients were evaluated for toxicity and 46 for response. The overall response rate was 32.5% (completed and partial response rates were 2.2% and 30.3%, respectively). The median time to progression was 5.1 months, median survival time was 10.2 months; and 1-year survival rate was 36.6%. The main hematologic toxicity consisted of 60.4% neutropenia, 39.5% thrombocytopenia. Grade III-IV neutropenia and thrombocytopenia were 20.8% and 12.5%, respectively. CONCLUSION: Six-hour prolonged infusion of low dose gemcitabine combined with cisplatin is a relatively safe and effective regimen for patients with advanced NSCLC.